Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia

Clinical Microbiology and Infection

Volumn 20, Issue 2, 2014, Pages 174-180

  Lemos, E V ^a,b   de la Hoz, F P ^a   Alvis, N ^c   Einarson, T R ^d   Quevedo, E ^b   Castaneda C ^a,b   Leon, Y ^e   Amado, C ^f   Canon O ^g   Kawai, K ^h  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Fundación Para El Desarrollo y Apoyo en Salud Internacional FUDASAI   (Colombia)

^c UNIVERSIDAD DE CARTAGENA   (Colombia)

^d UNIVERSITY OF TORONTO   (Canada)

^e Clínica del Occidente   (Colombia)

^f Hospital Occidente de Kennedy ESE   (Colombia)

^g UNIVERSIDAD SANTO TOMÁS   (Colombia)

^h TEMPLE UNIVERSITY   (United States)

Author keywords

Acinetobacter; Cost; Length of stay; Mortality; Resistance

Indexed keywords

CARBAPENEM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; COLOMBIA; CONTROLLED STUDY; FEMALE; HOSPITAL COST; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL;

ACINETOBACTER; ACINETOBACTER BAUMANNII;

ACINETOBACTER; COST; LENGTH OF STAY; MORTALITY; RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; BETA-LACTAM RESISTANCE; CARBAPENEMS; COHORT STUDIES; COLOMBIA; CROSS INFECTION; FEMALE; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84892488518     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12251     Document Type: Article

References (30)

1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358: 1271-1281.
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
3. Falagas ME, Karveli EA, Siempos II, Vardakas KZ. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect 2008; 136: 1009-1019.
4. Wagenvoort JH, Joosten EJ. An outbreak Acinetobacter baumannii that mimics MRSA in its environmental longevity. J Hosp Infect 2002; 52: 226-227.
5. Bernards AT, Frenay HM, Lim BT, Hendriks WD, Dijkshoorn L, van Boven CP. Methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii: an unexpected difference in epidemiologic behavior. Am J Infect Control 1998; 26: 544-551.
6. Sunenshine RH, Wright MO, Maragakis LL et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97-103.
7. Young L, Sabel A, Price C. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 2007; 28: 413-419.
8. Lemos EV, De la Hoz Restrepo F, Alvis N, Quevedo E, Canon O, Leon Y. Acinetobacter baumannii-related mortality in intensive care units in Colombia. Rev Panam Salud Publica 2011; 30: 287-294.
9. Lee NY, Lee HC, Ko NY et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28: 713-719.
10. Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 2012; 34: 124-137.
11. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012; 73: 354-360.
12. The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23: 106-108.
13. Kwon KT, Oh WS, Song JH et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59: 525-530.
14. Lautenbach E, Synnestvedt M, Weiner MG et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009; 30: 1186-1192.
15. Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009; 20: 540-544.
16. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. J Korean Med Sci 2012; 27: 471-475.
17. Sheng WH, Liao CH, Lauderdale TL et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 2010; 14: e764-e769.
18. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010; 38: 173-180.
19. Jamulitrat S, Arunpan P, Phainuphong P. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. J Med Assoc Thai 2009; 92: 413-419.
20. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 2011; 55: 4844-4849.
21. Aydemir H, Celebi G, Piskin N et al. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital. Jpn J Infect Dis 2012; 65: 66-71.
22. Deris Z, Shafei M, Harun A. Risk factors and outcomes of imipenem-resistant Acinetobacter bloodstream infection in North-eastern Malaysia. Asian Pac J Trop Biomed 2011; 1: 313-315.
23. Huang ST, Chiang MC, Kuo SC et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2012; 45: 356-362.
24. Chang HC, Chen YC, Lin MC et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator-associated pneumonia. J Formos Med Assoc 2011; 110: 564-571.
25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne (PA): Clinical Laboratory Standards Institute, 2006; 16th Informational Supplement M100-S16.
26. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332.
27. Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. Am J Med 1991; 91: 32S-38S.
28. Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther 2013; 11: 321-331.
29. Neidell MJ, Cohen B, Furuya Y et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 2012; 55: 807-815.
30. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-836.